Abstract

This work aims at the production of uniformly sized, equant shaped crystals using a direct nucleation control (DNC) strategy to help achieve enhanced manufacturability and bioavailability of the active pharmaceutical ingredients (API). A crystallization system equipped with in situ and external wet-milling devices was used. The experiments were conducted using mefenamic acid (MFA) mixed into solvents of 2-butanol and heptane with a mass ratio of 90:10. Firstly, a linear cooling crystallization was conducted as a reference case and also to identify suitable DNC set-points, which were then implemented using closed-loop feedback control based on the measurement of the FBRM counts. The in situ and external wet-milling based DNC approaches were compared in terms of temperature cycling efficiency and final crystal size and shape. This integrated wet-milling crystallization system demonstrated enhanced control over the crystal size distribution (CSD) and morphology compared to conventional cooling crystallization processes. In addition, the expansion of the design space was achieved by integrating wet-mill to DNC crystallization compared to the cooling crystallization-only process. In addition, enhanced control of the rate of nucleation and attrition is accomplished through combining wet-milling and DNC.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.